An Audio Review Journal for Surgeons: Bridging the Gap between Research and Patient Care


Investigator perspectives on the optimal clinical management strategies, emerging technologies and available adjunctive therapies in the management of local and systemic breast cancer. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.

Interview with William J Gradishar, MD

Track 1: Case discussion: A 37-year-old woman with a 3.5-cm, ER/PR-low, HER2-positive, clinically node-negative breast cancer (BC)
Track 2: Case discussion: A 58-year-old woman with T1cN1, ER-positive, HER2-negative BC and a 21-gene Recurrence Score® (RS) of 12
Track 3: MINDACT trial: Utility of the 70-gene signature in selecting patients with BC and 0 to 3 positive nodes for adjuvant chemotherapy
Track 4: Fertility issues in early BC
Track 5: Targeting the androgen receptor in patients with triple-negative BC (TNBC)
Track 6: Adjuvant bisphosphonates for early BC

Interview with Tari King, MD

Track 1: Case discussion: A 42-year-old woman with strongly ER/PR-positive, HER2-negative, node-negative multifocal invasive ductal carcinoma (IDC) and a 21-gene RS of 19
Track 2: Pathologic features and risks of developing BC for patients with lobular carcinoma in situ
Track 3: Comprehensive molecular portrait of invasive lobular BC
Track 4: Case discussion: A 36-year-old woman with a 4-cm, triple-negative IDC who wishes to have breast-conserving surgery (BCS) receives neoadjuvant cisplatin on a clinical trial
Track 5: Effect of ER and HER2 status on the use of neoadjuvant chemotherapy
Track 6: Use of the 21-gene RS to guide neoadjuvant therapy decision-making
Track 7: Case discussion: A 50-year-old perimenopausal woman who presents with a small group of microcalcifications in the right breast undergoes stereotactic biopsy and is diagnosed with intermediate-grade ER-positive ductal carcinoma in situ (DCIS)
Track 8: Benefits and limitations of the DCIS Score™
Track 9: Consensus guidelines on margins for BCS with whole-breast irradiation in patients with DCIS
Track 10: Complexities, challenges and advances in the treatment of DCIS

Interview with Joseph A Sparano, MD

Track 1: POSITIVE: An intergroup study evaluating pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine-responsive BC who desire pregnancy
Track 2: The DCIS Score as a tool for identifying risk of BC recurrence
Track 3: Use of the DCIS Score to facilitate decision-making regarding radiation therapy
Track 4: Case discussion: A 56-year-old woman with Stage IIIB (T3N1M0) ER/PR-positive, HER2-positive IDC initially treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab
Track 5: Case discussion: A 47-year-old premenopausal woman with Stage IIB (T2N1M0) ER/PR-positive, HER2-negative IDC and a 21-gene RS of 13 elects to receive endocrine therapy alone
Track 6: TAILORx: Results of the low-risk registry of a prospective trial of adjuvant systemic therapy for patients with ER-positive, HER2-negative BC based on the 21-gene RS
Track 7: Results of the Phase III West German Study Group PlanB trial: Effect of the 21-gene RS and concordance of prognostic markers in ER-positive, HER2-negative high-risk node-negative and node-positive BC
Track 8: Critical evaluation of the MINDACT trial results
Track 9: Perspective on the utility of the 70-gene signature in clinical practice
Track 10: Results of a prospective registry of patients with early BC for whom treatment decisions in clinical practice were made incorporating the 21-gene RS
Track 11: BC-specific survival in patients with ER-positive, node-negative invasive BC and 21-gene signature results in the SEER database
Track 12: Case discussion: A 50-year-old postmenopausal woman with Stage IIA, ER/PR-positive, HER2-negative IDC

Interview with Seema A Khan, MD, MPH

Track 1: Case discussion: A 52-year-old postmenopausal woman with ER/PR-positive, HER2-negative, node-negative IDC and an RS of 12 undergoes BCS
Track 2: Role of the 21-gene signature in neoadjuvant decision-making
Track 3: Case discussion: A 43-year-old woman with triple-negative, BRCA-negative IDC who deferred treatment for 1 year
Track 4: Adjuvant capecitabine in patients with HER2-negative BC and pathologic residual invasive disease after neoadjuvant chemotherapy
Track 5: Viewpoint on performing sentinel lymph node biopsy (SLNB) prior to the administration of neoadjuvant chemotherapy
Track 6: SLNB after neoadjuvant chemotherapy in patients with node-negative versus node-positive BC
Track 7: Approach to BRCA mutation testing in patients with TNBC
Track 8: Second opinion: Surgical resection of an intact primary tumor in a 49-year-old woman with ER/PR-negative, HER2-positive metastatic BC after complete response of a solitary liver metastasis to paclitaxel/trastuzumab/pertuzumab
Track 9: Status of ECOG-E2108: A Phase III trial evaluating early surgery versus standard palliative therapy in treating Stage IV BC
Track 10: Second opinion: A 41-year-old woman with ER/PR-positive, HER2-negative, clinically node-negative BC: Distinction between locally advanced and inflammatory disease
Track 11: Second opinion: Role of SLNB in the setting of recurrent BC
Track 12: Results from the Phase III CALOR (IBCSG 27-02, NSABP-B-37, BIG 1-02) trial: Adjuvant chemotherapy prolongs survival for patients with isolated local or regional recurrence of BC
 
FACULTY:
 
William J Gradishar, MD
Betsy Bramsen
Professor of Breast Oncology and Professor of Medicine
Deputy Director, Clinical Network
Robert H Lurie
Comprehensive Cancer Center of Northwestern University
Director, Maggie Daley Center for Women’s Cancer Care
Deputy Chief, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
 
Tari King, MD
Chief, Breast Surgery
Dana Farber/Brigham and Women’s Cancer Center
Associate Division Chief
for Breast Surgery
Brigham and Women’s Hospital
Associate Professor of Surgery
Harvard Medical School
Boston, Massachusetts
 
Joseph A Sparano, MD
Professor of Medicine and
Women’s Health
Albert Einstein College of Medicine
Associate Chairman, Department
of Oncology
Montefiore Medical Center
Bronx, New York
 
Seema A Khan, MD, MPH
Professor of Surgery
Bluhm Family Professor of
Cancer Research
Northwestern University Feinberg School of Medicine
Chicago, Illinois
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida